Abstract:Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discovery for COVID-19. In this study, we develop a novel drug repositioning method (VDA-KLMF) to prioritize possible anti-SARS-CoV-2 drugs integrating virus sequences, drug chemical structures, known Virus-Drug Associations, and Logistic Matrix Factorization with Kernel diffusion. First, Gaussian kernels of viruses and drugs are built based on known VDAs and nearest neighbors. Second, sequence similarity kernel of viruses and chemical structure similarity kernel of drugs are constructed based on biological features and an identity matrix. Third, Gaussian kernel and similarity kernel are diffused. Forth, a logistic matrix factorization model with kernel diffusion is proposed to identify potential anti-SARS-CoV-2 drugs. Finally, molecular dockings between the inferred antiviral drugs and the junction of SARS-CoV-2 spike protein-ACE2 interface are implemented to investigate the binding abilities between them. VDA-KLMF is compared with two state-of-the-art VDA prediction models (VDA-KATZ and VDA-RWR) and three classical association prediction methods (NGRHMDA, LRLSHMDA, and NRLMF) based on 5-fold cross validations on viruses, drugs, and VDAs on three datasets. It obtains the best recalls, AUCs, and AUPRs, significantly outperforming other five methods under the three different cross validations. We observe that four chemical agents coming together on any two datasets, that is, remdesivir, ribavirin, nitazoxanide, and emetine, may be the clues of treatment for COVID-19. The docking results suggest that the key residues K353 and G496 may affect the binding energies and dynamics between the inferred anti-SARS-CoV-2 chemical agents and the junction of the spike protein-ACE2 interface. Integrating various biological data, Gaussian kernel, similarity kernel, and logistic matrix factorization with kernel diffusion, this work demonstrates that a few chemical agents may assist in drug discovery for COVID-19.

Weighted hypergraph learning and adaptive inductive matrix completion for SARS-CoV-2 drug repositioning

An Ensemble Matrix Completion Model for Predicting Potential Drugs Against SARS-CoV-2

A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2

Computational Drug Repositioning Using Similarity Constrained Weight Regularization Matrix Factorization: A Case of COVID‐19

Drug Repositioning Based on Similarity Constrained Probabilistic Matrix Factorization: COVID-19 As a Case Study.

VDA-RWLRLS: an Anti-Sars-cov-2 Drug Prioritizing Framework Combining an Unbalanced Bi-Random Walk and Laplacian Regularized Least Squares

A Deep Learning Ensemble Approach to Prioritize Antiviral Drugs Against Novel Coronavirus SARS-CoV-2 for COVID-19 Drug Repurposing

Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization with Kernel Diffusion.

AntiViralDL: Computational Antiviral Drug Repurposing Using Graph Neural Network and Self-Supervised Learning.

Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures

Viral Drug prediction with Matrix Decomposition and Two-layer Heterogeneous Graph Inference

SANE: A Sequence Combined Attentive Network Embedding Model for COVID-19 Drug Repositioning.

A New Integrated Framework for the Identification of Potential Virus–drug Associations

Heterogeneous Graph Attention Networks for Drug Virus Association Prediction.

Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.

DeepVir -- Graphical Deep Matrix Factorization for "In Silico" Antiviral Repositioning: Application to COVID-19

A deep drug prediction framework for viral infectious diseases using an optimizer-based ensemble of convolutional neural network: COVID-19 as a case study

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19

GINCM-DTA: A Graph Isomorphic Network with Protein Contact Map Representation for Potential Use Against COVID-19 and Omicron Subvariants BQ.1, BQ.1.1, XBB.1.5, XBB.1.16

Machine-Learning Driven Drug Repurposing for COVID-19